Inventor · disambiguated record
Barry John Teobald
Also filed as: TEOBALD BARRY · TEOBALD BARRY JOHN
22 granted patents·13 pending applications·213 citations·filing 2000–2024
96Inventor score
Files withHEPTARES THERAPEUTICS LTD20SITRYX THERAPEUTICS LTD8ASTRAZENECA AB1BROWN GILES ALBERT1FORD RHONAN1
Top patents by PatentIndex Score
35 records- 0198US11352342B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Jun 7, 2022·9 cites·10 claims
- 0298US11254656B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Feb 22, 2022·10 cites·10 claims
- 0398US10961225B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Mar 30, 2021·11 cites·16 claims
- 0498US9670183B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2015·Granted Jun 6, 2017·34 cites·23 claims
- 0597US11773090B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Oct 3, 2023·6 cites·10 claims
- 0697US11319312B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted May 3, 2022·10 cites·20 claims
- 0797US10689368B2Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Jun 23, 2020·12 cites·20 claims
- 0897US10329278B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Jun 25, 2019·13 cites·17 claims
- 0997US10196380B2Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Feb 5, 2019·20 cites·16 claims
- 1096US10752610B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Aug 25, 2020·10 cites·20 claims
- 1196US9926297B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Mar 27, 2018·19 cites·18 claims
- 1295US10385039B2Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Aug 20, 2019·13 cites·20 claims
- 1394US12024499B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2022·Granted Jul 2, 2024·2 cites·7 claims
- 1493US10738029B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Aug 11, 2020·12 cites·6 claims
- 1592US10858352B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Dec 8, 2020·11 cites·20 claims
- 1692US10787447B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Sep 29, 2020·11 cites·18 claims
- 1787US11945801B2Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Apr 2, 2024·3 cites·15 claims
- 1877US10550089B2Inhibitors of protease-activated receptor-2HEPTARES THERAPEUTICS LTD·Filed 2017·Granted Feb 4, 2020·1 cites·7 claims
- 1975US2025115587A1Pyrazole derivatives as h4 antagonist compoundsBROWN GILES ALBERT·Filed 2024·Application pending·0 cites
- 2072US6767910B1Triazolo[4,5-d]pyrimidinyl compoundsASTRAZENECA AB·Filed 2000·Granted Jul 27, 2004·6 cites·13 claims
- 2166US12234227B2Pyrazole derivatives as H4 antagonist compoundsNXERA PHARMA UK LTD·Filed 2019·Granted Feb 25, 2025·0 cites·17 claims
- 2265US10995072B2Inhibitors of protease-activated receptor-2HEPTARES THERAPEUTICS LTD·Filed 2019·Granted May 4, 2021·0 cites·13 claims
- 2360US2025122212A1Novel compoundsSITRYX THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 2457US2024317775A1H4 Antagonist CompoundsHEPTARES THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2556US2023381132A1Novel compoundsSITRYX THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2656US2023399289A1Itaconic acid derivativesSITRYX THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2756US2023399287A1Novel compoundsSITRYX THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2853US2024335451A1Acrylamide derivatives useful as anti-inflammatory agentsSITRYX THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 2953US2024010606A1Fumarate derivatives and their medical useSITRYX THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 3045US2006128723A1Sulptionamide compounds that modulate chemokine receptor activity (CCR4)METE ANTONIO·Filed 2004·Application pending·0 cites
- 3143US12390437B2Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune responseSITRYX THERAPEUTICS LTD·Filed 2020·Granted Aug 19, 2025·0 cites·11 claims
- 3243US2023219907A1Carboxy derivatives with antiinflamatory propertiesSITRYX THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 3342US2006122195A1Sulphonamide compounds that modulate chemokine receptor activity (ccr4)HARRISON RICHARD·Filed 2004·Application pending·0 cites
- 3442US2010113510A1Quinuclidinol derivatives as muscarinic receptor antagonistsFORD RHONAN·Filed 2007·Application pending·0 cites
- 3539US2004214864A1Novel compoundsFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Barry John Teobald files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →